Price
No data yet.
Social Signal Score
Revenue
$173.91MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bobak R. Azamian
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 370
- Beta
- 0.51
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 7.74
Financials
Revenue
$173.91M+420.2%Net Income
$-18.55MEBITDA
$-12.68MFree Cash Flow
$62.70MEPS (diluted)
$-0.43Shares Outstanding (diluted)
43.39M+912.6%Operating Expenses
$181.71MCash & Debt
$449.69MReturn of Capital
$0.00Revenue by Segment (annual)
$451.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $451.36M | $-66.42M | $-1.59 |
| 2024 | $182.95M | $-115.55M | $-3.07 |
| 2023 | $17.45M | $-135.89M | $-4.62 |
| 2022 | $25.82M | $-62.09M | $-2.52 |
| 2021 | $57.03M | $-13.83M | $-0.67 |
| 2020 | $0.00 | $-26.81M | $-1.32 |
| 2019 | $0.00 | $-4.67M | $-0.24 |
| 2018 | $0.00 | $-1.32M | $-0.31 |
Valuation
TARShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th H.C.
View source ↗ - Newsglobenewswire.com·8d ago·Negative
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation for oral gildeuretinol for the trea
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $-1.53 per share
Typical surprise +7.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.43 vs $-0.19miss
- Wed, May 6$-0.16 vs $-0.40beat
- Mon, Feb 23$-0.20 vs $-0.10miss
- Tue, Nov 4$-0.30 vs $-0.35beat
- Wed, Aug 6$-0.48 vs $-0.33miss
- Thu, May 1$-0.64 vs $-0.69beat
Estimates and results for TARS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TARS officers and directors.
- Bought
- —
- Sold
- $9.7m
0 trades
31 trades
- Azamian Bobak R.sold
- Azamian Bobak R.sold
- Farrow Jeffrey Ssold
- Goodrich Katherinesold
- Link William J Phdsold
- Link William J Phdsold
- Neervannan Seshadrisold
- Whitfield Dianne C.sold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.